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Abstract 
Results of mutagenesis and selection of spontaneous second-site revertants of the yeast ADP/ATP  cartier AAC2 is described. 
Currently, 50 mutants have been made in AAC2 at 35 locations. Yeast carrying mutations at K38, K48, R96, D149, R152, R204, D249, 
R252, R253, R254 and R294 are all unable to grow on glycerol. Seven of these mutants have yielded second-site revertants when plated 
on rich yeast media containing lycerol and ethanol. The R96 mutants and the R254 and R253 mutants produce similar changes in the 
AAC2 molecule because the same sites are affected by their revertant mutations. This system of mutations and revertants i now poised to 
yield insights into the dynamics of ADP and ATP transport, and mitochondrial carrier structure in general. 
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1. Introduction 
The rapid progress in sequencing the yeast genome will 
soon allow us to identify all the mitochondrial carriers in a 
single-celled organism. Even now, at the end of 1995, 70% 
of the yeast genome is in Genbank and 31 open reading 
frames appear to be mitochondrial carriers. This extrapo- 
lates to 44 carriers in the complete genome. There is a 
significant degree of redundancy in yeast, so 44 genes does 
not imply 44 functions. Analysis of random lacZ insertions 
by Burns et al. [1] showed that only 25% of gene disrup- 
tions had a detectable phenotype. This will probably be 
true for the carrier genes as well. The ADP/ATP carrier is 
represented by three genes, AACI, AAC2 and AAC3. 
Only AAC2 is normally expressed. The phosphate carrier 
MIR1 has another silent partner YER053c that is 38% 
identical in amino acid sequence. This is greater than the 
percent identity between yeast and mammalian phosphate 
carriers so the YER053c gene can be assumed to be a 
phosphate carrier as well. Since the knockout of MIR1 is 
unable to grow on non-fermentable carbon sources [2], 
YER053c is not functionally redundant under normal cir- 
cumstances. The two genes MRS3 and MRS4 that are high 
copy suppressors of mitochondrial splicing defects [3] are 
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clearly isoforms (75% identical), as are YMC1 [4] and 
YMC2 (Genbank Z35973) with 69% identity. The two 
genes YEL006w (Genbank U18530) and YIL006w 
(Genbank Z38113) are 58% identical and probably have 
the same function. Therefore, of the 31 known carriers in 
yeast at least five are redundant (16%). This analysis leads 
to an estimate of about 37 unique functions among the 44 
carriers predicted to exist in yeast. This number is three 
times the known functions attributed to mitochondrial car- 
tiers by LaNoue and Schoolwertb [5], and more than twice 
the number given by Palmieri [6]. Of the 31 carriers 
identified by sequence homology in yeast only four func- 
tions have been determined (the ADP/ATP carrier, the 
citrate carrier [7], the phosphate carrier [8] and the FAD 
carrier, FLX1 [9,10]) accounting for only seven of the 
sequences. So far, the a-ketoglutarate cartier has not been 
identified in yeast and the uncoupler protein is strictly 
mammalian. 
Clearly, one of the major undertakings in mitochondrial 
carrier research will be to discern what the normal sub- 
strates are for this moderately sized protein family. The 
problem of going from sequence to function has recently 
been reviewed by Oliver, with special reference to yeast 
[11]. The first step along this path will be the construction 
of knockouts of all these genes to see what if any pheno- 
type they have. So far, 14 yeast carriers have been dis- 
rupted, but only five are unable to grow on glycerol. Of 
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these, PET8 [12] and RIM2 [13] still have no defined 
substrates. The more direct approach would be to express 
all of the carriers in Escherichia coli and screen them for 
activity in a series of reconstitution assays. This approach 
could succeed in identifying those functions that are known 
to be in yeast, but cannot be identified by sequence alone. 
The reconstitution method has been tried with the citrate 
carrier [7] and the phosphate carrier [14], though efforts to 
express AAC2 in E. coli have not succeeded. Some 
potential pitfalls of this strategy are codon bias differences 
between yeast and E. coli. This is a particular problem for 
the arg codons AGA and AGG and the leu codon CGA. 
AGA and AGG are the most common codons for arginine 
in yeast making up 69% of the Arg codon usage. In E. 
coli, they are among the rarest of codons, comprising only 
7% of arg codon usage. CGA is also very rare in E. coli, 
at just 3% of leu codons. In yeast CGA is 14%. There are 
19 of these undesirable codons in AAC2, including a run 
of three AGA codons in a row at the conserved Arg triplet. 
Perhaps more important than defining function for these 
carriers will be the continuing task of figuring out how 
they transport heir substrates across the mitochondrial 
inner membrane. This will depend on a handful of carriers 
that can be isolated in large quantity from mammalian 
tissue, or that have defined systems for mutagenesis and 
expression in yeast or E. coli. These include AAC2, the 
major isoform of the yeast ADP/ATP carrier, the mam- 
malian heart AAC, the uncoupler protein that is now 
expressed in yeast [15,16], the phosphate carrier and the 
citrate carrier. For reviews of mitochondrial cartier struc- 
ture, function and evolution, see Refs. [6,17-21]. 
2. Mutagenesis of the yeast AAC2 
Fig. l shows the residues of the AAC2 that have been 
mutated in our laboratory [18,22]. The six transmembrane 
segment model has only four charged amino acids in the 
membrane region. These are K38, R96, R204 and R294. 
All of these residues have been modified and all mutants 
are unable to grow on glycerol/ethanol p ates. These are 
referred to as gly- mutants. In addition to these conspicu- 
ous charges, the triple arginine sequence in the third 
domain (252-254) has also been modified and all three of 
these charges are also required for growth on glycerol. 
The molecule is drawn to emphasize the three-domain 
structure of the protein. In this structure, certain features 
are repeated in the AAC2 and indeed in all the ADP/ATP 
carriers with known sequence (about 30 sequences). An 
alignment of 119 mitochondrial carriers or 31 yeast carri- 
ers as of March 1, 1996 is available on the World Wide 
Web at http://drnelson.utmem.edu/homepage.html. For 
a select number of positions, this conservation of structure 
extends to nearly all the cartier sequences, independent of 
substrates transported. These residues include the negative 
charges at the bottom of the first, third and fifth helices, 
Fig. 1. Location of mutants in the yeast AAC2. K38A, K48A, C73S, R88[A,D], R96[A,D,H,L,P,T], DI49[G,S], [RI52A + L218S], KI79M, [K1791 + 
K182I], R204L, W235F,C244S, P247G, D249S, R252I, R253I, R2541, C271S and R294A were made by site-directed mutagenesis. D26[E,V], G30[C,V], 
S33[I,N], E45[G,Q], N531, FI05[L,V], A106T, R152K, Y207H, G209S, G234S, W235L, R252T, C288Y, A299S, I302T, Y305H, and L308P arose as 
second-site r vertants. Many of these are described in more detail in Refs. I I 7,18,22,27]. 
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and the positive charges two amino acids below them. We 
have mutated all six of these charges in AAC2 and find 
that five mutants are gly-. Only E45 does not seem to be 
required. 
Not all of the charged residues we have mutated are 
critical for function. The aspartate at position 26 is not 
required, and the conserved R88 at the bottom of the 
second helix is also dispensable. K179 and K182, labeled 
by pyridoxal phosphate from the outside surface [23], and 
thought o penetrate deep into the membrane, can also be 
neutralized without serious consequences. 
All four cysteines in AAC2 have been modified. C73, 
C244, C271 and C288 are all non-essential for growth on 
glycerol. Work is now under way to mutate all of these 
residues in the same molecule to make a cysteine free 
protein. Such a molecule could have cysteine added back 
at any desired location, as long as that site was not 
essential. The usefulness of such constructs would be 
invaluable in helix contact mapping and for introduction of 
specific labels into the protein. 
Fifteen other sites in AAC2 have been mutated, either 
directly or through selection of second site revertants ( ee 
below). All of these mutants are gly ÷, although many of 
them do not exist as single mutants, but only in conjunc- 
tion with another gly- mutant used for selection of rever- 
tants. The proline at 247 was mutated to glycine without 
affecting rowth on glycerol. This was surprising because 
the prolines at the bottom of the first third and fifth helices 
are conserved in nearly all mitochondrial carriers. Serine is 
found in plants and lower eukaryotes in domain two, but 
otherwise, replacement of the proline is extremely rare. 
Only two cases are seen and these are both from system- 
atic sequencing of the yeast genome. Chromosome XII 
(U19028.14) and chromosome XIII (Z48756.3) have phe 
and thr respectively in domain two, though this may be 
due to sequencing errors. Glycine never occurs at this 
location in 119 carriers, though the lack of a side chain 
may make folding at this position very flexible and lead to 
the correct structure ven without he proline. 
3. Second-site revertants 
All of the gly- mutants of AAC2 involve loss of a 
charge, either positive or negative. Neutral residues tested 
so far have not been essential for activity when mutated. 
All of the glycerol-negative mutants have been used to 
select second-site revertants. Not every mutant has yielded 
revertants. Those that do tend to fall into one of two main 
categories. Either they are intragenic or extragenic. The 
intragenic revertants are much more common. Only a few 
extragenic mutants are available and these have not been 
characterized. The existence of extragenic mutants trongly 
suggests that another protein or proteins interact with the 
ADP/ATP carrier in the membrane. One candidate for 
such an interaction is the F o portion of the ATP synthase. 
The F 0 has been shown to be involved with AAC2 by a 
series of experiments involving fluorescence quenching of 
pyranine by oligomycin [24]. The quenching can be blocked 
or reversed by adding atractyloside or bongkrekic acid, 
specific inhibitors of AAC2. Bongkrekic acid does not 
affect oligomycin-dependent quenching in strains of yeast 
lacking AAC2. We are in the process of sequencing sub- 
unit 9 and subunit 6 of the ATPase from our extragenic 
revertants to see if they might be the sites of these 
revertant mutations. 
The intragenic mutants can be point mutants or recom- 
bination products with the AAC3 gene [25]. This gene is 
highly similar to AAC2 and it has not been deleted from 
the genome of our host yeast. Occasionally we find our 
gly mutants have recombined with AAC3 to recover the 
wild-type sequence at the mutation, plus some AAC3 
sequence on either side. These are not of much interest o 
us and eventually we will delete the AAC3 gene to prevent 
their happening at all. The point mutants can be same-site 
or second-site revertants. Same-site revertants are selected 
against by making a double or triple nucleotide change in 
the original mutation. This requires multiple changes to go 
back to the wild-type sequence. Still, this type of same-site 
revertant does occur. For example, a revertant of R152A 
resulted in A152K, restoring the positive charge with a 
different amino acid at this site. 
The really interesting revertants are second-site rever- 
tants. These also fall into two categories. Either they 
involve mutation of neutral residues to other neutral 
residues, or they result in loss of a complementary charge. 
These latter mutants imply that a charge pair may exist 
between the two sites in the wild-type protein. We have 
never seen a revertant yet that introduced a new charge at 
a second site, though that was the original expectation for 
the intrahelical R294A revertants. If a charge was removed 
from a transmembrane h lix, it made sense that the same 
charge would reappear on an adjacent transmembrane h - 
lix by selection for revertants. This phenomenon was 
observed for mutants of the DCCD binding subunit of the 
bacterial F~F 0 ATPase [26]. A negative charge was re- 
moved and a new negative charge appeared on the second 
transmembrane helix of this small protein. When the 
R294A mutant was selected on YPGE plates, three inde- 
pendent revertants all showed loss of the negative charge 
at E45, either to gin or gly. The E45G or E45Q mutants 
were gly ÷ when separated from their parent mutation 
R294A. This made it impossible to select backwards for 
the mutation of R294 starting with the E45 mutants. For a 
more detailed account of the biochemistry involved in the 
R294A mutant see Refs. [17,27] 
One interesting feature of AAC2 is the homology be- 
tween domains. R294 is homologous to position 96 in the 
second transmembrane h lix, and both sites contain argi- 
nine. Furthermore, E45 is homologous to D149, both with 
a negative charge. There was a chance that R96 and D149 
were in another charge pair, and this might be detectable 
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by selection of second-site revertants tarting with mutants 
of R96. We actually had six different mutants of R96 
available, (A, D, H, L, P and T) and all were gly-. Some 
of these were not suitable for selection, because arginine 
could reappear with one nucleotide change. After many 
attempts to find second-site revertants, R96L gave $33I 
and R96A gave three revertants, D26V, C288Y and Y305H. 
None of the revertants involved D149. 
The data were suggestive that there was not a charge 
pair between R96 and D149 even though they were homol- 
ogous to E45 and R294. Apparently, though the molecule 
has three-fold homology, there is not strict symmetry 
between all of the domains. The occurrence of D26V 
might suggest a charge interaction between R96 and D26, 
but this is unlikely because the two are quite far apart and 
there are three other revertants of R96 mutants that do not 
involve charges. It is more probable that D26V has more 
to do with a geometric hange at a particular location than 
with a charge interaction between D26 and R96. The 
revertants of R96 are far apart in the sequence and on 
opposite sides of the membrane from each other. The 
interpretation of these mutations is not clear. 
The R96 revertants just mentioned are revertants involv- 
ing mainly neutral residues changed into other neutral 
residues. There is another large group of these kind of 
revertants. They were selected starting from mutants of the 
arg triplet [22]. The sequence RRRMMM at 252-257 in 
AAC2 is highly conserved among ADP/ATP  carriers. 
Each Arg was mutated to fie separately and the gly-  
mutants were selected for regain of function on 
glycerol/ethanol p ates. R252I never gave any revertants. 
R253I gave four and R254I gave 1 !. These results show a 
strong influence of sequence position on the ability to 
revert. The three arginines, though adjacent in the se- 
quence, are clearly under different constraints imposed by 
the function of the protein. R252 seems to be indispensable 
or nearly so, while mutations at R254 are not nearly so 
unsalvagable. 
One unexpected feature of the 15 revertants was their 
location. Only N53I was on the matrix side of the mem- 
brane with the arg triplet. All the others were either on the 
cytoplasmic side or they were in the membrane near the 
cytoplasmic side. All revertants were distant from the arg 
triplet in the sequence. It is likely that N53 is involved in a 
polar interaction with R253, but the other residues were 
probably not in physical contact with the arg triplet. We 
speculated that the geometry on the far side of the mem- 
brane was altered by mutation of the arginines, through a 
shift in the bottom of helix 5. The revertant mutations were 
able to restore this defect in a variety of ways. 
Some of the revertants from the arg triplet mutants were 
at identical positions to revertants of R96 mutants. Y305H 
occurred starting from R96A and R253I. $33I was found 
starting from R96L and $33N was found starting with 
R254I. D26E was a revertant of R254I and D26V was a 
revertant of R96A. This additional mutant at D26 supports 
the argument made earlier that the D26V mutant does not 
indicate a charge pair with R96. The fact that the same 
sites are being affected by two very different mutations, 
leads to a prediction that both R96 and the arg triplet are 
interacting with a common third site. Presumably, this 
third site would be a negatively charged residue. The 
disruption of this common interaction could then be re- 
sponsible for the similar alteration of the AAC2 molecule. 
D149 was already suggested as a possible interacting 
residue with R96 based on homology to E45 and R294. 
However, no evidence from revertants upported this idea. 
To confirm or deny such a possibility, double mutants 
were constructed with changes at both R96 and D149. 
These were all gly . When the double mutant R96T and 
D149G was selected for revertants, one revertant was 
found. It was G30V. G30C was previously shown to be a 
revertant of R254I, which adds to the evidence that R96 
mutants and arg triplet mutants have similar effects on 
AAC2 structure. It is surprising to us that a single change 
at G30 could resurrect he double mutant of R96T and 
D149G. Both of these mutants alone are gly-. The mutants 
that are shared revertants coming from both R96 and the 
arg triplet are all found in a limited area at the top of 
transmembrane s gments 1 and 6. These two helices are 
probably adjacent in light of the E45-R294 charge pair. 
The significance of this localized effect is not known and 
cannot be known unless more details of the AAC2 struc- 
ture can be determined. 
4. Future directions 
The selection for second-site revertants has been very 
successful so far and we will continue to exploit it. A 
phrase often heard in Mike Douglas' lab was "Let the 
protein talk to you." The selection process has already 
yielded an interesting collection of charge pair revertants 
in addition to the R294-E45 pair, but these cannot be 
discussed more fully here. 
In the absence of a crystal structure, the understanding 
of mitochondrial carrier structure will depend on building 
up a detailed set of structural constraints uch as charge 
pairs and perhaps engineered disulfide bonds. We are 
actively moving into this phase of research now. Of course 
the nature of the dimer interaction eeds to be clarified and 
this question may also be resolved using a combination of 
genetics and biochemistry. 
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